NVLNF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVLNF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Novelion Therapeutics's retained earnings for the quarter that ended in Mar. 2019 was $-854.1 Mil.
Novelion Therapeutics's quarterly retained earnings declined from Sep. 2018 ($-802.9 Mil) to Dec. 2018 ($-822.3 Mil) and declined from Dec. 2018 ($-822.3 Mil) to Mar. 2019 ($-854.1 Mil).
Novelion Therapeutics's annual retained earnings declined from Dec. 2016 ($-587.2 Mil) to Dec. 2017 ($-714.0 Mil) and declined from Dec. 2017 ($-714.0 Mil) to Dec. 2018 ($-822.3 Mil).
The historical data trend for Novelion Therapeutics's Retained Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novelion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | |||||||||||
Retained Earnings | Get a 7-Day Free Trial | -511.33 | -534.34 | -587.21 | -713.97 | -822.30 |
Novelion Therapeutics Quarterly Data | ||||||||||||||||||||
Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | |
Retained Earnings | Get a 7-Day Free Trial | -746.80 | -778.06 | -802.87 | -822.30 | -854.15 |
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Novelion Therapeutics (OTCPK:NVLNF) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Kevin Kotler | 10 percent owner | C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Capital, Llc | 10 percent owner | 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Broadfin Healthcare Master Fund Ltd | 10 percent owner | C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108 |
Stonepine Capital, L.p. | 10 percent owner | 919 NW BOND STREET, SUITE 204, BEND OR 97703 |
Michael Dennis Price | officer: Chief Financial Officer | |
Benjamin Harshbarger | officer: See Remarks | ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
Mark Dipaolo | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
John J Orloff | director | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Stephen L Sabba | director | DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791 |
Mark Corrigan | director | |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
John C Thomas | director | 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
Murray Stewart | officer: Executive Vice President, R&D | C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Mary T Szela | director, officer: Chief Executive Officer | 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
From GuruFocus
By Marketwired Marketwired • 11-21-2018
By Marketwired Marketwired • 02-28-2019
By Marketwired Marketwired • 02-06-2019
By Marketwired Marketwired • 08-22-2019
By Marketwired Marketwired • 08-30-2019
By Marketwired Marketwired • 07-03-2018
By GlobeNewswire GlobeNewswire • 03-31-2019
By Marketwired Marketwired • 10-08-2019
By GlobeNewswire GlobeNewswire • 08-21-2019
By Marketwired Marketwired • 06-01-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.